Literature DB >> 3141174

Susceptibility of clinical isolates of Campylobacter pylori to twenty-one antimicrobial agents.

C A McNulty1, J C Dent.   

Abstract

The MICs of 21 antimicrobial agents were determined for 97 clinical isolates of Campylobacter pylori. The beta-lactams (penicillin, ampicillin, cefoxitin and cephalexin), macrolides (erythromycin and azithromycin), quinolones (ciprofloxacin and ofloxacin), nitrofurans, gentamicin and tetracycline all had MIC90 values of less than or equal to 0.5 mg/l. Aztreonam, flucloxacillin, amifloxacin and rifampicin had moderate activity. All isolates were resistant to vancomycin, cefsulodin and amphotericin B. Five percent of the strains were inhibited by 8 mg/l of polymyxin. Of the oral agents tested, the nitrofurans and ampicillin are probably the most appropriate antimicrobial agents. Azithromycin and the oral form of cefuroxime are promising alternatives. Cefsulodin, vancomycin and amphotericin B would be suitable constituents of selective media for isolation of Campylobacter pylori.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3141174     DOI: 10.1007/bf01962617

Source DB:  PubMed          Journal:  Eur J Clin Microbiol Infect Dis        ISSN: 0934-9723            Impact factor:   3.267


  19 in total

1.  Gastrointestinal absorption and metabolism of two 35S-labelled ampicillin esters.

Authors:  A Swahn
Journal:  Eur J Clin Pharmacol       Date:  1976-02-06       Impact factor: 2.953

Review 2.  Inocula for antimicrobial sensitivity testing: a critical review.

Authors:  P Gilbert; M R Brown; J W Costerton
Journal:  J Antimicrob Chemother       Date:  1987-08       Impact factor: 5.790

3.  Bismuth/ofloxacin combination for duodenal ulcer.

Authors:  E Bayerdörffer; T Simon; C Bästlein; R Ottenjann; G Kasper
Journal:  Lancet       Date:  1987-12-19       Impact factor: 79.321

4.  In-vitro sensitivity of Campylobacter pyloridis to furazolidone.

Authors:  A Howden; P Boswell; F Tovey
Journal:  Lancet       Date:  1986-11-01       Impact factor: 79.321

Review 5.  Chemotherapeutic properties of prominent nitrofurans.

Authors:  R E Chamberlain
Journal:  J Antimicrob Chemother       Date:  1976-12       Impact factor: 5.790

6.  Antibacterial activity of a monocyclic beta-lactam SQ 26,776.

Authors:  H C Neu; P Labthavikul
Journal:  J Antimicrob Chemother       Date:  1981-12       Impact factor: 5.790

7.  Identification of Campylobacter pyloridis isolates by restriction endonuclease DNA analysis.

Authors:  W Langenberg; E A Rauws; A Widjojokusumo; G N Tytgat; H C Zanen
Journal:  J Clin Microbiol       Date:  1986-09       Impact factor: 5.948

8.  The in vitro and in vivo activity of ciprofloxacin.

Authors:  H J Zeiler; K Grohe
Journal:  Eur J Clin Microbiol       Date:  1984-08       Impact factor: 3.267

9.  The minimum inhibitory and bactericidal concentrations of antibiotics and anti-ulcer agents against Campylobacter pyloridis.

Authors:  C S Goodwin; P Blake; E Blincow
Journal:  J Antimicrob Chemother       Date:  1986-03       Impact factor: 5.790

10.  Response of Campylobacter pyloridis to antibiotics, bismuth and an acid-reducing agent in vitro--an ultrastructural study.

Authors:  J A Armstrong; S H Wee; C S Goodwin; D H Wilson
Journal:  J Med Microbiol       Date:  1987-12       Impact factor: 2.472

View more
  21 in total

1.  Direct and indirect methods of measuring Helicobacter pylori drug susceptibility in vitro.

Authors:  A McLaren
Journal:  Mol Biotechnol       Date:  1999-12-15       Impact factor: 2.695

2.  In vitro activities of new oral beta-lactams and macrolides against Campylobacter pylori.

Authors:  J A García-Rodríguez; J E García Sánchez; M I García García; E García Sánchez; J L Muñoz Bellido
Journal:  Antimicrob Agents Chemother       Date:  1989-09       Impact factor: 5.191

3.  Susceptibility of Helicobacter pylori to metronidazole.

Authors:  M López-Brea; E Martín; C López-Lavid; J C Sanz
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1991-12       Impact factor: 3.267

4.  In vitro selection of resistant Helicobacter pylori.

Authors:  C E Haas; D E Nix; J J Schentag
Journal:  Antimicrob Agents Chemother       Date:  1990-09       Impact factor: 5.191

5.  Role of metronidazole resistance in therapy of Helicobacter pylori infections.

Authors:  H Rautelin; K Seppälä; O V Renkonen; U Vainio; T U Kosunen
Journal:  Antimicrob Agents Chemother       Date:  1992-01       Impact factor: 5.191

6.  In vitro activities of new quinolones against Helicobacter pylori.

Authors:  M Carbone; M T Fera; V Cecchetti; O Tabarrini; E Losi; V Cusumano; G Teti
Journal:  Antimicrob Agents Chemother       Date:  1997-12       Impact factor: 5.191

Review 7.  Spectrum of activity of azithromycin.

Authors:  J D Williams
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1991-10       Impact factor: 3.267

8.  Antibacterial properties of lansoprazole alone and in combination with antimicrobial agents against Helicobacter pylori.

Authors:  M Nakao; M Tada; K Tsuchimori; M Uekata
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1995-05       Impact factor: 3.267

9.  Effect of transport medium and transportation time on culture of Helicobacter pylori from gastric biopsy specimens.

Authors:  R A Veenendaal; A T Lichtendahl-Bernards; A S Peña; H P Endtz; C P van Boven; C B Lamers
Journal:  J Clin Pathol       Date:  1993-06       Impact factor: 3.411

Review 10.  Azithromycin. A review of its antimicrobial activity, pharmacokinetic properties and clinical efficacy.

Authors:  D H Peters; H A Friedel; D McTavish
Journal:  Drugs       Date:  1992-11       Impact factor: 9.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.